Peer-reviewed veterinary case report
Tyrosine kinase inhibitors as a treatment for dog mast cell tumors
By Coelho YNB et al.·2023·Institute of Biomedical Sciences, Brazil·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor.
- Species:
- dog
Plain-English summary
A dog with a mast cell tumor (a type of skin cancer) was treated with either a common chemotherapy drug called vinblastine or a newer treatment known as a tyrosine kinase inhibitor (TKI). The review of multiple studies found that dogs receiving TKIs had a higher rate of tumor response, meaning their tumors shrank more often than those treated with vinblastine. However, dogs treated with vinblastine lived longer overall and had better progression-free survival compared to those on TKIs. For dogs with specific genetic mutations, TKIs showed improved survival rates.
People also search for: dog mast cell tumor treatment · tyrosine kinase inhibitors for dogs · vinblastine for dog cancer
Abstract
The current gold standard treatment for canine mast cell tumors (MCT) uses vinblastine sulfate (VBL) as chemotherapy, although tyrosine kinase inhibitors (TKI) have recently been shown to be worthy candidates for treatment. This systematic review aimed to analyze the overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and complete (CR) or partial response (PR) in dogs with MCT treated with TKI compared to standard VBL treatment. The systematic review was registered in the Open Science Framework (OSF) database under the identifier 10.17605/OSF.IO/WYPN4 (https://osf.io/). An electronic search was performed in nine databases. References from eligible studies were also selected to find more registers. A total of 28 studies met the eligibility criteria, and one more was recovered from the references of eligible studies, totaling 29 selected studies. The overall response rate, complete response, and partial response were higher in dogs treated with tyrosine kinase inhibitors than in dogs treated with vinblastine. The overall survival and progression-free survival of vinblastine-treated dogs were higher compared to tyrosine kinase inhibitors-treated dogs. Dogs with mutated KIT treated with tyrosine kinase inhibitors have longer overall survival and progression-free survival compared to those treated with vinblastine. It is important to consider the limitation of the study which should temper the interpretation of the results, videlicet, the extracted data lacked sample standardization and included variables such as animal characteristics, mutation detection methods, tumor characteristics, and treatment types which may have influenced the outcome of the study.<h4>Systematic review registration</h4>https://osf.io/, identifier: 10.17605/OSF.IO/WYPN4.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/37360406